Table 3.

Evaluation of secondary endpoints in the ITT population.

	Current practice	NMJ-targeted
	n=44	n=44
MAS response at 12 weeks
n (%)	19 (48.7%)*	13 (33.3%)†
Adj difference		−0.1324; 95% CI (–0.3531 to 0.0884)
P value		0.24
GAS score improvement
n (%)	25 (61.0%)‡	21 (63.6%)§
P value		0.5747
Spasticity related pain, VAS (mean±SD)
Baseline	14.32±22.64	21.66±28.97
Week 4	10.30±19.99¶	14.05±27.50**
Mean change	−4.35±12.29	−5.8±23.07
Decrease of mean (%)	30.4	26.8
Injection-related pain VAS (at first visit)
Mean±SD	30.68±27.33**	25.67±25.37††
Difference		−5.01
P value		0.406

*5 patients missing 12-week MAS evaluation.

†5 patients missing 12-week MAS evaluation.

‡3 patients missing GAS evaluation.

§11 patients missing GAS evaluation.

¶1 patient missing VAS evaluation.

**7 patients missing VAS evaluation.

††8 patients missing VAS evaluation.

GAS, Goal Attainment Scaling; MAS, Modified Ashworth Scale; NMJ, neuromuscular junction; VAS, Visual Analogue Scale.